Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE When treating hormone receptor-positive/HER2-negative MBC patients with endocrine therapy, it is important to differentiate patients with lung metastases from those with liver metastases. 31373147 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 GeneticVariation disease BEFREE Whole-exome sequencing of the primary HER2-negative breast cancer and its HER2-negative synchronous liver metastasis from a 46-year-old female revealed the presence of an activating and clonal HER3 G284R mutation. 25953157 2015
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Univariate analysis revealed that platelet-derived growth factor AA (PDGFAA) in DV blood (dPDGFAA) (<i>P</i> = 0.001), PDGFAA in PV blood (pPDGFAA) (<i>P</i> = 0.007), and human epidermal growth factor receptor-2 in PV blood (pHER2) (<i>P</i> = 0.001), pMMP7 (<i>P</i> = 0.028), pRANTES (<i>P</i> = 0.013), and pEGF (<i>P</i> = 0.007) were significantly correlated with synchronous liver metastasis. 28275303 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Lung and brain metastases were common in hormone receptor-/human epidermal growth factor receptor 2+ and hormone receptor-/human epidermal growth factor receptor 2- subtypes, and patients with hormone receptor+/ human epidermal growth factor receptor 2+ and hormone receptor-/human epidermal growth factor receptor 2+ subtypes were more prone to liver metastases. 28653887 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE HER2 was positive in nearly 52 % of the primary tumors, and these expressed HER2 in corresponding lymph node and liver metastases in 93 and 100 % of the cases, respectively. 24643685 2014
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Therefore, trastuzumab may be an effective agent in the chemotherapeutic treatment of liver metastases in patients with HER2-positive gastric adenocarcinoma. 25526216 2014
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE For distant metastases, the results showed that there was a high probability of bone metastasis in HR-positive groups, brain and liver metastasis in HER2-positive groups, and lung metastasis in the TN group. 28472761 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE In multivariate analysis, only subtype (ER+/HER2+ vs. ER-/HER2-; HR = 0.77; P = 0.02) and liver metastases (HR = 1.36; P = 0.01) were prognostic for survival. 31035019 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE The expression of c-erbB-2 protein in colorectal cancer tissue correlates closely with liver metastasis but not with lymphatic or lung metastases. 11032920 2000
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE In another patient, the HER-2 gene was amplified in the primary tumor but not in the liver metastasis. 15786420 2005
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 GeneticVariation disease BEFREE One of these patients with human epidermal growth factor receptor 2 mutation recurred early with liver metastasis. 24803549 2014
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE HER2 expression was detected by immunohistochemistry in 84 GC patients with liver metastases. 22654433 2012
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE Based on the Her2/neu-scoring system, moderate to strong SSTR2A expression was observed in 121 of 156 (78%) liver metastases. 28213807 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE C-erbB-2 was found more often in advanced cancers (P < 0.05), papillary adenocarcinoma (P < 0.01), nonscirrhous cancer (P < 0.05), and cancers with liver metastasis (P < 0.01). 8397058 1993
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE The HER2 positivity was 37.2 % (35/94) in GCLM patients and 21 % (61/290) in the overall GC patients. 27324991 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE On binary regression analysis, hyperattenuation of the tumor (odds ratio [OR], 4.68; <i>p</i> < 0.001) and hepatic metastasis (OR, 4.43; <i>p</i> = 0.001) were significant independent factors that predict HER2-positive cancers. 28860898 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE Furthermore, breast cancer patients with hepatic metastasis and those with elevated s-erbB-2 serum levels above 40 U/ml had limited response to hormone or chemotherapy. 12065844 2002
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE A 42-year-old woman with HER2-positive salivary duct carcinoma of the parotid gland with bone and liver metastases had CR with TPH and remains in remission on maintenance trastuzumab and pertuzumab. 30478962 2018
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer. 25915155 2015
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE HER-2/neu mRNA levels were significantly higher (P = 0.032) in tumors associated with liver metastases but not with tumor location or size. 12097278 2002
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE HR+/HER2+ had higher odds of liver metastases. 27975154 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE Moreover, c-erbB-2 mRNA predicted the development of liver metastases in tumours that had not metastasised to lymph nodes (p = 0.002). 9137444 1997
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Patients with a HER2-/HoR+ status had more bone metastasis, whereas patients with a HER2+/HoR- status had an increased incidence of liver metastasis. 28345619 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Compared with metastatic FBC, metastatic MBC patients had a higher proportion of ⩾60 years old, central portion of the breast, surgery, simultaneous bone and lung metastasis, while the proportion of Her2+/HR-, triple negative, liver metastasis only, and simultaneous bone and liver metastasis was lower. 31798694 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Liver metastases are very common in metastatic breast cancer (MBC); current treatments for these lesions are based on systemic chemotherapy, endocrine- or human epidermal growth factor receptor 2 (HER2)-targeted therapy, and palliative therapy. 30041178 2018